Related Experiment Video
Updated: Aug 6, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia
1Department of Clinical Science, University of Bergen, Bergen, Norway.
Introduction:
Approximately one-third of patients with acute myelogenous leukemia (AML) harbor mutations in the fms-like tyrosine kinase 3 (FLT3) gene. The features regarding prognostic impact of FLT3 mutated AML have been widely investigated and debated in the last decades, and the significance of this mutation is constantly evolving.
Areas Covered:
In this article, the significance of the FLT3 mutation and various aspects of this mutation are discussed in the light of new understanding and research progress in past years. The recently updated European Leukemia Net (ELN) guidelines are reviewed and discussed, special emphasis given to the the improvement in therapeutic approaches for FLT3 mutated AML.
Expert Opinion:
Aspects related to FLT3 mutated AML include the type of mutation in addition to FLT3-internal tandem duplication (ITD) length, location, and allelic ratio. Furthermore, the coexistence of cytogenetic variants and molecular genetic mutations utterly complicate the evaluation of the prognostic impact. In addition, introduction of FLT3 inhibitors and establishment of measurable residual disease (MRD) monitoring have entered the treatment and evaluation armamentarium in the handling of AML patients, resulting in improved prognosis for these patients. However, future research to optimize the treatment of FLT3 mutated AML is highly desired.
Insights
Approximately one-third of acute myelogenous leukemia (AML) patients have FLT3 mutations. New FLT3 inhibitors and MRD monitoring improve treatment outcomes, but further research is needed.
Area of Science:
- Hematology
- Molecular Oncology
- Leukemia Research
Background:
- About one-third of acute myelogenous leukemia (AML) patients harbor fms-like tyrosine kinase 3 (FLT3) gene mutations.
- The prognostic impact of FLT3 mutations in AML has been extensively studied and debated.
- Understanding of FLT3 mutations in AML is continuously evolving with new research.
Purpose of the Study:
- To discuss the significance of FLT3 mutations in AML based on recent research.
- To review updated European Leukemia Net (ELN) guidelines for FLT3-mutated AML.
- To highlight advancements in therapeutic approaches for FLT3-mutated AML.
Main Methods:
- Review of current literature and recent research progress on FLT3 mutations in AML.
- Analysis of updated European Leukemia Net (ELN) guidelines.
- Discussion of prognostic factors including mutation type, ITD characteristics, and co-occurring mutations.
Main Results:
- FLT3 mutation characteristics (ITD length, location, allelic ratio) and co-mutations complicate prognostic evaluation.
- Introduction of FLT3 inhibitors and measurable residual disease (MRD) monitoring have improved treatment outcomes.
- Updated ELN guidelines incorporate new therapeutic strategies for FLT3-mutated AML.
Conclusions:
- FLT3 inhibitors and MRD monitoring represent significant advancements in managing FLT3-mutated AML.
- Despite improvements, further research is essential to optimize treatment strategies.
- Personalized treatment approaches considering mutation specifics are crucial for better prognosis.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
